News

Welcome to the CLINUVEL News page. Discover the latest in clinical, corporate, and regulatory updates.

Media release: FDA, CLINUVEL TO DISCUSS SCENESSE® AT PRE-NDA MEETING

2016 Announcements

11.10.2016

CLINUVEL Confirms Date of Annual General Meeting

2016 Announcements

09.10.2016

Chair’s Letter

2016 Announcements

19.09.2016

Appendix 4E – Preliminary Final Report 2015/16

2016 Announcements

24.08.2016

Lapse and Forfeit of Unlisted Conditional Performance Rights

2016 Announcements

22.08.2016

CLINUVEL Newsletter – August 2016

2016 Announcements

14.08.2016

Notice of Initial Substantial Holder

2016 Announcements

09.08.2016

Appendix 3Y

2016 Announcements

03.08.2016

Appendix 3B

2016 Announcements

02.08.2016

CLINUVEL completes pre-clinical study of SCENESSE® as combination therapy

2016 Announcements

02.08.2016

Appendix 4C – Q4 FY16

2016 Announcements

28.07.2016

FDA accepts SCENESSE® clinical data package for NDA submission

2016 Announcements

17.07.2016

FDA awards SCENESSE® Fast Track designation for treatment of EPP

2016 Announcements

05.07.2016

.

Go To Top